Precidian ETFs Trust - GSK plc ADRhedged

Key Updates

GSKH rebounded 4.20% to $76.60 since the March 20 report, recovering a portion of the recent correction from February's $83.54 peak. The rally was supported by positive ViiV Healthcare HIV treatment trial data and a UK meningitis outbreak that highlights demand for GSK's Bexsero vaccine. The stock remains 8.31% below its February high but maintains strong YTD performance of 12.31%, indicating the underlying uptrend remains intact despite the consolidation phase.

Current Trend

GSKH demonstrates a positive YTD performance of 12.31% and exceptional 6-month gains of 35.94%, confirming a robust uptrend that began in late 2025. The recent correction from the $83.54 February peak to a low near $73.51 on March 20 represents a healthy 12% pullback within the broader uptrend. The current price of $76.60 shows the stock is attempting to establish a higher low, with immediate resistance at the $80-$83 zone and support at the $73-$74 level tested during the March correction. The 1-month decline of 7.50% reflects consolidation rather than trend reversal, while the strong 5-day gain of 3.62% suggests renewed buying interest.

Investment Thesis

The investment thesis centers on GSK's strategic portfolio transformation under CEO Luke Miels, who is actively diversifying beyond HIV medications ahead of patent expiries. The $950 million acquisition of 35Pharma expands GSK into cardiovascular medicine, addressing a critical gap in the portfolio. ViiV Healthcare's HIV pipeline remains robust, with lotivibart demonstrating 94% viral suppression rates in 12-month data and potential for twice-yearly dosing, which could extend GSK's leadership in HIV treatment beyond current patent timelines. The company benefits from an established vaccine franchise, evidenced by the UK meningitis outbreak creating immediate demand for Bexsero. While Haleon's disappointing performance reflects consumer market weakness, its separation from GSK is complete, limiting direct impact on GSKH performance.

Thesis Status

The investment thesis has strengthened materially since the March 20 report. The positive lotivibart data validates GSK's HIV pipeline strategy, demonstrating the company can develop next-generation treatments to offset patent expiries. The 94% viral suppression rate with IV dosing and potential twice-yearly administration represents a significant advancement in HIV treatment that could maintain ViiV Healthcare's market position. The $950 million 35Pharma acquisition confirms management's commitment to portfolio diversification into cardiovascular medicine, a market with substantial growth potential. The UK meningitis outbreak, while a public health concern, demonstrates the value of GSK's vaccine portfolio and provides near-term revenue visibility. The thesis of successful portfolio transformation under new leadership is progressing as anticipated.

Key Drivers

ViiV Healthcare's lotivibart phase IIb trial results showed 94% viral suppression with IV dosing and 82% with subcutaneous administration at 12 months, supporting progression to twice-yearly dosing evaluation. This ultra-long-acting HIV treatment could extend GSK's competitive position in the $30+ billion HIV therapeutics market beyond current patent timelines. The UK meningitis B outbreak escalating from level 1 to potentially level 2 or 3 creates immediate demand for GSK's Bexsero vaccine, particularly among university students following superspreading events at Canterbury nightclub. GSK's $950 million acquisition of 35Pharma marks strategic entry into cardiovascular medicine, diversifying the portfolio under CEO Luke Miels' leadership as the company faces pressure from upcoming HIV patent expiries. Haleon's £65 million Shanghai plant investment and China expansion demonstrate the spun-off consumer health entity's independent growth trajectory, though its disappointing sales results have limited direct impact on GSK.

Technical Analysis

GSKH established a February peak at $83.54 before entering a correction phase that bottomed at approximately $73.51 on March 20, representing a 12% pullback. The current price of $76.60 shows the stock recovering 4.20% from the recent low, suggesting a potential higher low formation within the broader uptrend. Key resistance levels are $80.00 (psychological level) and $83.54 (February high), while support is established at $73.50-$74.00 (March low). The 6-month gain of 35.94% and YTD performance of 12.31% confirm the primary trend remains bullish. The 1-month decline of 7.50% appears to be consolidation within the uptrend rather than a reversal, with the recent 5-day rally of 3.62% indicating renewed momentum. The stock needs to reclaim the $80 level to confirm the correction has ended and resume the advance toward the February highs.

Bull Case

• ViiV Healthcare's lotivibart achieved 94% viral suppression in 12-month phase IIb data with potential for twice-yearly dosing, positioning GSK to maintain HIV market leadership beyond current patent expiries and address the $30+ billion HIV therapeutics market with next-generation ultra-long-acting treatments. Source
• The $950 million 35Pharma acquisition provides strategic entry into cardiovascular medicine under CEO Luke Miels, diversifying the portfolio into a high-value therapeutic area where GSK currently has limited presence and creating long-term growth opportunities beyond the HIV franchise. Source
• The UK meningitis B outbreak escalating to potentially level 2 or 3 creates immediate demand for GSK's Bexsero vaccine, particularly among university students, demonstrating the value and revenue visibility of the company's established vaccine franchise. Source
• Strong 6-month price appreciation of 35.94% and YTD gains of 12.31% demonstrate sustained investor confidence in GSK's strategic transformation, with the recent correction to $73.51 representing a healthy consolidation that has established a potential higher low at a 12% pullback from the February peak.
• The lotivibart trial showed low confirmed virologic failure rates of 4% for IV dosing and 6% for subcutaneous administration versus 4% in the control group, validating the safety and efficacy profile necessary for regulatory approval and commercial success in the competitive HIV treatment market. Source

Bear Case

• CEO Luke Miels faces significant pressure to develop new medicines to offset upcoming patent expiries of blockbuster HIV drugs, creating execution risk as the company must successfully commercialize pipeline assets like lotivibart and the 35Pharma cardiovascular drug to maintain revenue growth. Source
• The 35Pharma acquisition targets an early-stage high blood pressure drug for $950 million, representing substantial capital deployment on an unproven asset in a competitive cardiovascular market where GSK currently lacks expertise and commercial infrastructure. Source
• GSKH remains 8.31% below the February peak of $83.54 and has declined 7.50% over the past month, indicating investor uncertainty about the company's ability to execute its portfolio transformation strategy and offset HIV patent expiries with new revenue sources.
• Lotivibart's subcutaneous dosing showed lower viral suppression rates of 82% compared to 94% for IV administration, potentially limiting patient convenience and commercial appeal if the more practical subcutaneous route proves less effective than intravenous dosing. Source
• While the UK meningitis outbreak creates near-term vaccine demand, the Health Security Agency considers widespread contagion risk remote, limiting the duration and magnitude of incremental Bexsero revenue and highlighting the episodic nature of outbreak-driven vaccine sales. Source